EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Retrospective Analysis of the Potential Impact of Differences in Aggregates on Clinical Immunogenicity of Biosimilars and their Reference Products

Cristina Fernandez-Mendivil iD, Niamh M Kinsella iD, Hans C Ebbers iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Cristina Fernandez-Mendivil und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biogen International GmbH, Baar, Switzerland. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aggregates, in particular high molecular weight species (HMWs), have been linked to increased immunogenicity. The current understanding on the impact of HMWs is mainly based on in vitro and nonclinical studies and there are only limited data available associating differences in HMWs in marketed monoclonal antibodies (mAbs) to clinical outcomes. Biosimilars offer a unique opportunity to study the potential association between quality parameters and clinical outcomes. We performed a retrospective evaluation to investigate the association between HMW content and reported antidrug‐antibody (ADA) incidence in 30 full‐length biosimilar mAbs approved in the European Union and the United States. Information for HMW content and ADA incidence were collected from publicly available sources. Differences in HMW content between biosimilars and their reference products (RPs) ranged from −0.75 to 1.65% with slightly higher differences observed in antineoplastic products as compared with immunosuppressant products. The difference in the ADA incidence between the RP and the biosimilar for the programs studied ranged from −11.0 to 18.5%. No association was observed between differences in HMW content and reported ADA incidence, in neither phase I nor phase III studies. Our results show that the limited differences in the content of HMWs between marketed biosimilars and reference mAbs were not associated with differences in reported immunogenicity, determined as incidence of ADAs and neutralizing ADAs in comparative clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsHumansUnited StatesRetrospective StudiesAntibodies, MonoclonalImmunosuppressive AgentsEuropean Union

Substanzen

Biosimilar PharmaceuticalsAntibodies, MonoclonalImmunosuppressive Agents

Autor:innen und Institutionen

  • Biogen International GmbH, Baar, Switzerland.
  • Biogen Idec UK Ltd., Berkshire, UK.

ORCID-Profile: Cristina Fernandez-Mendivil, Niamh M Kinsella, Hans C Ebbers

Zitieren

APA

Fernandez-Mendivil, C., Kinsella, N. M., & Ebbers, H. C. (2024). A Retrospective Analysis of the Potential Impact of Differences in Aggregates on Clinical Immunogenicity of Biosimilars and their Reference Products. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3180

Vancouver

Fernandez-Mendivil C, Kinsella NM, Ebbers HC. A Retrospective Analysis of the Potential Impact of Differences in Aggregates on Clinical Immunogenicity of Biosimilars and their Reference Products. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3180

BibTeX
@article{FernandezMendivil2024,
  author = {Fernandez-Mendivil, Cristina and Kinsella, Niamh M and Ebbers, Hans C},
  title = {A Retrospective Analysis of the Potential Impact of Differences in Aggregates on Clinical Immunogenicity of Biosimilars and their Reference Products},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3180}
}
Kostenlos starten →